We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Kymera Therapeutics Inc | NASDAQ:KYMR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 36.01 | 14.48 | 36.20 | 0 | 11:34:07 |
From May 2023 to May 2024
By Dean Seal
Kymera Therapeutics said it has received orphan drug designation from regulators for its acute myeloid leukemia treatment.
The U.S. Food and Drug Administration has granted the designation for KT-253, which targets a crucial regulator of the most common tumor suppressor and has been shown to rapidly induce cancer cell death.
Orphan-drug designation is a special status given to drugs that show promise for potentially treating rare, or orphan, diseases that have fewer than 200,000 cases a year in the U.S.
Shares slipped 2% to $24.15 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 22, 2023 09:06 ET (13:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Kymera Therapeutics Chart |
1 Month Kymera Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
